• Chembio Diagnostics (Medford, New York) said it has developed Dual Path Platform (DPP) technology for rapid diagnostic tests that offers significant advantages over the lateral flow technology used in commercially available rapid diagnostic tests. A presentation on DPP at the International Symposium on Immunobiologicals and Human Health which ends today in Rio de Janeiro, Brazil, found that the independent flow paths for DPP sample and conjugate assays increase the efficiency of antibody binding to the immobilized test antigen, which leads to improved sensitivity in several of the different assays being developed. Chembio has completed feasibility studies on a number of rapid test applications utilizing DPP technology for HIV, tuberculosis and other diseases. These studies confirm the advantages of DPP technology over single-path lateral flow designs, the company said.